Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire•27/10/2026•07:30 ET
0
Key Highlights
- ➤Cash $187.7M, expected to fund planned operations through at least end-2028
- ➤TibuSHIELD enrollment completed with 247 participants; topline data remains on track for Q4 2026
- ➤TibuSURE enrollment completed with 91 participants; topline data remains on track for H1 2027
- ➤NEXUS-PMR FDA-cleared and remains on track to initiate by year-end 2026
- ➤Q3 net loss $25.8M, or $0.20 per share, versus $20.0M loss in 2025
Expert Statements
Sandeep Kulkarni, Co-founder and Chief Executive Officer of Zura
“Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027”
Sandeep Kulkarni, Co-founder and Chief Executive Officer of Zura
“We continue to believe deeply in tibulizumab’s potential to address complex immune biology and unmet needs across indications, including in PMR, where we will be starting the NEXUS-PMR study by end of year. With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab’s unique potential.”
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
* TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026; enrollment completed with 247 participants randomized, exceeding target
Get started
Create a free account to read the full story.